Boomers Should Not ...
Health Care: Drugs
Idenix Pharmaceuticals Inc. (IDIX: NASDAQ)
$4.15 0.08 | 1.97%
05/22/13 - 04:00 PM ET
Insider Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Net Insider Transaction | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares Bought | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Institutional Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Total Shares Held | 140.00M | 140.15M | 140.79M | 142.24M | 140.32M | 140.22M | 141.29M |
| Shares Bought | 18.89M | 18.54M | 19.71M | 20.51M | 44.97M | 44.46M | 44.62M |
| Shares Sold | 11.63M | 13.10M | 13.05M | 12.69M | 15.36M | 17.42M | 15.93M |
Portfolios with IDIX
- Portfolio NameUser Type
- ProSeth Klarman - Baupost Group
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- Userdonnieny7 Portfolio 1 Specu...
- ContributorStocks Rising On Unusual Vo...
- Usernew
- UserLong Term Stock Picks
- ContributorStocks Under-$10 Setting Up...
Latest IDIX Headlines from TheStreet
- Idenix Announces Data Presentation At The 48th Annual Meeting Of The European Association For The Study Of The Liver (EASL) 04.08.13 | 04:04 pm
- Idenix Loses First Phase Of Patent Dispute With Gilead Sciences 03.25.13 | 07:03 am
- Stock Futures Rise as Cyprus Deal Is Clinched 03.25.13 | 06:03 am
- Idenix Pharmaceuticals Announces Decision By The United States Patent And Trademark Office Patent Trial And Appeal Board In The First Phase Of The Interference 03.22.13 | 04:03 pm
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.26.13 | 04:02 pm
- Idenix Pharmaceuticals Reports Fourth Quarter And Year Ended 2012 Financial Results 02.25.13 | 04:02 pm
- Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha 02.11.13 | 09:02 pm
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.05.13 | 04:02 pm
- Idenix Pharmaceuticals Provides Update On IDX184 And IDX19368 Development Programs 02.04.13 | 04:02 pm
Press Releases for IDIX
- Idenix Pharmaceuticals Announces Declaration Of A Patent Interference By The USPTO - PR Newswire 03.06.12 | 08:03 am
- Idenix Pharmaceuticals Elects Thomas Hodgson As Chairman Of The Board And Appoints Michael Wyzga To Its Board Of Directors - PR Newswire 03.01.12 | 04:03 pm
- Idenix Pharmaceuticals To Present At Three Upcoming Investor Conferences - PR Newswire 02.29.12 | 04:02 pm
- Idenix Pharmaceuticals To Present At The Citi Global Healthcare Conference - PR Newswire 02.21.12 | 04:02 pm
- Idenix To Host Conference Call Discussing Fourth Quarter And Year End 2011 Financial Results And Pipeline Update - PR Newswire 02.16.12 | 08:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.07.12 | 04:02 pm
- BioMed Realty Trust To Acquire Cambridge Place For $119 Million - PR Newswire 02.06.12 | 05:02 pm
- Idenix Announces Removal Of The Partial Clinical Hold On HCV Nucleotide Inhibitor, IDX184 - PR Newswire 02.03.12 | 08:02 am
- Idenix Reports Advancement Of HCV Development Pipeline - PR Newswire 01.09.12 | 07:01 am
- Idenix Reports Positive Interim Data For HCV Nucleotide Inhibitor, IDX184 - PR Newswire 01.09.12 | 07:01 am
Partner Headlines for IDIX
- DFC Global Lowers Outlook and 2 Other Stocks At 52-Week Lows - Wall St. Cheat Sheet 04.02.13 | 09:04 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November - Benzinga 12.01.12 | 01:12 pm
- New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 - Seeking Alpha 11.30.12 | 08:11 am
- UPDATE: Deutsche Bank Initiates Coverage on Idenix Pharmaceuticals with Buy Rating, $7 PT - Benzinga 11.28.12 | 09:11 am
- Morning Market Losers - Benzinga 09.19.12 | 09:09 am
- Idenix's Candidate on Clinical Hold - Analyst Blog - NASDAQ 08.30.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - NASDAQ 08.27.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - Zacks 08.27.12 | 06:08 pm
- UPDATE: Oppenheimer Maintains Idenix Pharmaceuticals at Perform Following Clinical Hold on IDX19368 - Benzinga 08.27.12 | 01:08 pm
